Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients.

Authors:
Lutsey PL; Horvath KJ; Fullam L; Moll S; Rooney MR and 2 more

Journal:
Thromb Haemost

Publication Year: 2018

DOI:
10.1055/s-0038-1625985

PMCID:
PMC6203330

PMID:
29448297

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Thromb Haemost

Abbreviation: Thromb Haemost

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-…
Puchstein D; Kork F; Schöchl H and 2 more (2023) - Transparency Score: 3/6
Activation of the Acute-Phase Response in Hemophilia.
Knowles LM; Wolter C; Menger MD and 5 more (2023) - Transparency Score: 3/6
Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thr…
Akbulut AC; Arisz RA; Baaten CCFMJ and 62 more (2023) - Transparency Score: 2/6
Characterization and Usefulness of Clot-Fibrinolysis Waveform Analysis in Critical Care Patients wi…
Tsuchida T; Hayakawa M; Kumano O. (2023) - Transparency Score: 2/6
Comprehensive Analysis of Hemophilia A (CAHEA): Towards Full Characterization of the F8 Gene Varian…
Liu Y; Li D; Yu D and 10 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest Dr. Stephan Moll has consulted for Janssen (manufacturers Xarelto/rivaroxaban), Boehringer-Ingelheim (Pradaxa/dabigatran etexilate and Praxbind/idarucizumab) and Portola (betrixaban and andexanet). The commercial entities had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. No other authors have any conflicts of interest to disclose."

Evidence found in paper:

"Funding/Support This work was supported by non-sponsored McKnight Land-Grant Professorship funds to Dr. Lutsey and R01 HL131579. "

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025